Anne Birgitte Als
Overview
Explore the profile of Anne Birgitte Als including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
34
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holmsten K, Omland L, Als A, Agerbaek M, Dohn L, Lindberg H, et al.
Bladder Cancer
. 2024 Jul;
8(1):71-80.
PMID: 38994523
Background: Neoadjuvant cisplatin-based chemotherapy is standard care prior to radical cystectomy in patients with muscle-invasive bladder cancer (MIBC). Objective: To assess efficacy and safety of two commonly used neoadjuvant schedules...
2.
Omland L, Stormoen D, Dohn L, Carus A, Als A, Jensen N, et al.
Bladder Cancer
. 2024 Jul;
7(4):413-425.
PMID: 38993987
Background: Investigating the effect of newly approved oncological drugs in the real-world is warranted. With emerging novel treatments rapidly being approved for urothelial tract cancers, we aimed to assess real-world...
3.
Ronde H, Kronborg C, Hoyer M, Hansen J, Bak M, Agergaard S, et al.
Acta Oncol
. 2023 Sep;
62(10):1222-1229.
PMID: 37683054
Background: Patients with stage II seminoma have traditionally been treated with photons to the retroperitoneal and iliac space, which leads to a substantial dose bath to abdominal and pelvic organs...
4.
Tolstrup L, Als A, Carus A, Dahlrot R, Dohn L, Hollander-Mieritz C, et al.
Acta Oncol
. 2023 Mar;
62(3):329-333.
PMID: 36995173
No abstract available.
5.
Larsen S, Logager V, Bylov C, Nellemann H, Agerbaek M, Als A, et al.
J Cancer Res Clin Oncol
. 2022 Apr;
149(3):1221-1230.
PMID: 35389110
Purpose: Concerns of imaging-related radiation exposure in young patients with high survival rates have increased the use of magnetic resonance imaging (MRI) in testicular cancer (TC) stage I. However, computed...
6.
Omland L, Lindberg H, Carus A, Als A, Jensen N, Taarnhoj G, et al.
Eur Urol Open Sci
. 2021 Aug;
24:1-8.
PMID: 34337488
Background: Real-world treatment patterns and survival outcomes of locally advanced, unresectable, and metastatic urinary tract cancer (mUTC) patients have not previously been studied in a nationwide, population-based cohort. Objective: To...
7.
Gitz-Johansen G, Als A, Pallesen K
Clin Case Rep
. 2021 Jul;
9(7):e04444.
PMID: 34322243
This case report presents an acute painful skin reaction several years after injection of site-enhancing oils (SEO) induced by chemotherapy. This case exemplifies the long-term dangerous side effects of the...
8.
Maibom S, Jakobsen J, Aagaard M, Als A, Petersen P
Scand J Urol
. 2020 Aug;
54(4):334-338.
PMID: 32734838
The role of pelvic lymph node dissection (PLND) is still debated in patients with N3 stage penile cancer. In Denmark this subgroup of patients is in general managed with an...
9.
Als A, Sengelov L, von der Maase H
Acta Oncol
. 2007 Sep;
47(1):110-9.
PMID: 17851853
Background: Chemotherapy with gemcitabine and cisplatin (GC) is an active regimen in advanced transitional cell carcinoma (TCC). Traditionally, GC has been administered as a 4-week schedule. However, an alternative 3-week...
10.
Als A, Sengelov L, von der Maase H
Eur Urol
. 2007 Mar;
52(2):478-86.
PMID: 17383078
Objective: The objective was to evaluate response and survival, as well as efficacy of subsequent supplementary treatment and follow-up strategy in patients with locally advanced transitional cell carcinoma of the...